Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

16.06 -0.04 (-0.25%)
Streaming Delayed Price Updated: 2:38 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,426,366
Open 16.12
Bid (Size) 16.05 (82)
Ask (Size) 16.06 (46)
Prev. Close 16.10
Today's Range 16.02 - 16.17
52wk Range 12.28 - 17.15
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
From Takeda Pharmaceutical Company Limited
Via Business Wire

Performance

YTD
+1.90%
+1.90%
1 Month
-3.49%
-3.49%
3 Month
+4.35%
+4.35%
6 Month
+10.38%
+10.38%
1 Year
+11.45%
+11.45%

More News

Read More
Takeda Pharmaceutical Ltd. (NYSE: TAK) Highlighted for Surprising Price Action
Via Investor Brand Network
FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq
Via Benzinga
U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
Via Benzinga
Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues
Via Benzinga
Earnings Scheduled For May 11, 2023
Via Benzinga
Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
From Takeda Pharmaceutical Company Limited
Via Business Wire
Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations
From Corza Medical Inc.
Via GlobeNewswire
Cannabis Movers & Shakers: Latest Appointments From Khiron, MariMed, Equilibria & More
Via Benzinga
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
Via The Motley Fool
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Via The Motley Fool
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
Via Benzinga
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
From Takeda Pharmaceutical Company Limited
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
From Centogene NV
Via GlobeNewswire
Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens
Via Investor's Business Daily
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
Via Talk Markets
The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat
Via Investor's Business Daily
Etsy To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners
From Takeda Pharmaceutical Company Limited
Via Business Wire
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.